These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1219 related articles for article (PubMed ID: 30481203)

  • 1. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis.
    Korfei M; Skwarna S; Henneke I; MacKenzie B; Klymenko O; Saito S; Ruppert C; von der Beck D; Mahavadi P; Klepetko W; Bellusci S; Crestani B; Pullamsetti SS; Fink L; Seeger W; Krämer OH; Guenther A
    Thorax; 2015 Nov; 70(11):1022-32. PubMed ID: 26359372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
    Epstein Shochet G; Wollin L; Shitrit D
    Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
    Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y
    Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
    Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
    Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors.
    Didiasova M; Singh R; Wilhelm J; Kwapiszewska G; Wujak L; Zakrzewicz D; Schaefer L; Markart P; Seeger W; Lauth M; Wygrecka M
    FASEB J; 2017 May; 31(5):1916-1928. PubMed ID: 28148565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.
    Conforti F; Davies ER; Calderwood CJ; Thatcher TH; Jones MG; Smart DE; Mahajan S; Alzetani A; Havelock T; Maher TM; Molyneaux PL; Thorley AJ; Tetley TD; Warner JA; Packham G; Ganesan A; Skipp PJ; Marshall BJ; Richeldi L; Sime PJ; O'Reilly KMA; Davies DE
    Oncotarget; 2017 Jul; 8(30):48737-48754. PubMed ID: 28467787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
    Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
    Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
    Korfei M; Mahavadi P; Guenther A
    Cells; 2022 May; 11(10):. PubMed ID: 35626663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
    Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
    Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation.
    Vu TN; Chen X; Foda HD; Smaldone GC; Hasaneen NA
    Respir Res; 2019 Sep; 20(1):206. PubMed ID: 31511015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
    Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
    Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.
    Ghebremariam YT; Cooke JP; Gerhart W; Griego C; Brower JB; Doyle-Eisele M; Moeller BC; Zhou Q; Ho L; de Andrade J; Raghu G; Peterson L; Rivera A; Rosen GD
    J Transl Med; 2015 Aug; 13():249. PubMed ID: 26231702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice.
    Sanders YY; Hagood JS; Liu H; Zhang W; Ambalavanan N; Thannickal VJ
    Eur Respir J; 2014 May; 43(5):1448-58. PubMed ID: 24603818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models.
    Yu W; Guo F; Song X
    Pharm Biol; 2017 Dec; 55(1):450-455. PubMed ID: 27937011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis.
    Di Fazio P; Schneider-Stock R; Neureiter D; Okamoto K; Wissniowski T; Gahr S; Quint K; Meissnitzer M; Alinger B; Montalbano R; Sass G; Hohenstein B; Hahn EG; Ocker M
    Cell Oncol; 2010 Jan; 32(4):285-300. PubMed ID: 20208142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirfenidone in idiopathic pulmonary fibrosis.
    Maher TM
    Drugs Today (Barc); 2010 Jul; 46(7):473-82. PubMed ID: 20683502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo.
    Ma Z; Zhao C; Chen Q; Yu C; Zhang H; Zhang Z; Huang W; Shen Z
    Pulm Pharmacol Ther; 2018 Dec; 53():100-106. PubMed ID: 30394340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.